Chao Ming Zhao, China Biologic’s President & Chief Executive Officer, said, ‘We have become pleased to have the SFDA’s authorization to enter clinical trials for our human fibrinogen product. Our human fibrinogen is manufactured using our developed fresh manufacturing process internally, which improves product quality, compared with available items in the Chinese market. The brand new process increases plasma utilization and production efficiency also. We plan to protected a patent for our manufacturing invention. We believe this new product will progress our plasma protein development pipeline. The phase III clinical trials are anticipated to last about 2 yrs, after which we will begin commercial sales and production, assuming the clinical trials prove that the merchandise provides the secure and efficient treatments we expect.Related StoriesGreater evidence-based help needed for depressed employees – New report from THE TASK FoundationInnovative single-use torque instruments utilize hard polycarbonate from BayerInnovative single-make use of torque instruments utilize tough polycarbonate from Bayer The Oregonian: Cover Oregon: Health Exchange Workers Committed Three Data Breaches Last Week Officials at Oregon's wellness exchange are reviewing privacy protections after workers there committed three personal data breaches in 3 days. On Nov. 20, Valarie Henderson of Salem opened her mail from Cover Oregon to locate a packet that included not just a copy of her application she'd done weeks before, but private information from two other people that included name, address and public security numbers .org with permission from the Henry J.